INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42m ago
HOUSE PTR2m ago
SEC 13F2m ago
ROBINHOOD CHAIN2m ago
SEC FORM 4/Grant or awardVerified data

Salus Thomas D. reported LFCR

Chief Legal & Administration · LIFECORE BIOMEDICAL, INC. \DE\ · Common Stock

Side
A
Value
—
Shares
30.0K
Price
—
Executed
Mar 2, 2026
Disclosed
Mar 2, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Mar 2 executedMar 2, 2026 disclosed

LFCR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+5 / 25

    No reported dollar value · 12.4% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LFCR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    21
    JH
    Johnson Paul HaroldDirector
    LFCRLIFECORE BIOMEDICAL, INC. \DE\
    Grant or award
    		A—
    25.9K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    16
    JP
    Josephs PaulDirector, Chief Executive Officer
    LFCRLIFECORE BIOMEDICAL, INC. \DE\
    Tax withholding
    		F$185K
    40.4K sh
    		May 20, 2026May 21, 2026
    traded May 20, 2026
    		+1dSEC FORM 4

    Evidence

    16
    SD
    Salus Thomas D.Chief Legal & Administration
    LFCRLIFECORE BIOMEDICAL, INC. \DE\
    Tax withholding
    		F$128K
    24.6K sh
    		Apr 14, 2026Apr 16, 2026
    traded Apr 14, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002062209-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 2, 2026
    Published
    Mar 2, 2026
    Ingested by INSIDER
    Nov 5, 04:14 UTC
    Last re-read
    Nov 5, 04:14 UTC

    Extracted facts

    Filer
    Salus Thomas D.
    Role
    Chief Legal & Administration
    Transaction
    Grant or awardAs filed: “A”
    Asset
    LIFECORE BIOMEDICAL, INC. \DE\
    Ticker
    LFCR
    Shares
    30.0K
    Execution date (reported)
    Mar 2, 2026
    Owned after transaction
    271.0K shares
    Days from execution to publication
    0

    What this establishes

    Salus Thomas D. filed this Form 4 reporting a grant or award of LFCR on Mar 2, 2026. It became public on Mar 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Legal & Administration
    Salus Thomas D.cik:0002062209
    Issuer
    LIFECORE BIOMEDICAL, INC. \DE\cik:0001005286

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.